A Translational Research-Program for Compound Race Pathology: Five Framework-Distinct Trial-Design Templates
Zenodo (CERN European Organization for Nuclear Research) June 21, 2026 Tomas Pødenphant Lund
A framework is only useful if it can be proven wrong in a measurable way. This paper turns the compound-race-pathology framework into five concrete trial designs that others can run, refine, or disprove, each specifying in advance what would count as failure. The protocols cover treatment-resistant depression using ketamine plus CBT consolidation or psilocybin with substrate-vector-matched integration, a long COVID multi-target factorial trial, a multi-axis biomarker profiling approach for depression, and CAR-T plus tolerance-stabilization for autoimmune disease. Each trial design includes substrate-vector entry criteria, 4D stratification analysis, and framework-pivotal R-condition specifications. The author, an independent researcher without clinical credentials, explicitly invites domain-expert collaboration and notes that specific intervention development requires standard clinical methodology.